The Silicon Review - Best Business Review Magazine 50 Most Trustworthy Companies 2019 | Page 115

B-Cell Signaling
Interfering with the communication signals of
malignant B cells is a potential strategy for treating
some types of cancer.
• AbbVie is a leader in the research of Bruton’s
tyrosine kinase (BTK), a key enzyme in the B cell
receptor signaling complex that plays an important
role in the survival and expansion of malignant B
cells.1
• AbbVie is researching other B cell signaling
pathways.
Regulated Cell Death - Apoptosis
Apoptosis is a form of regulated cell death, a natural
process that eliminates damaged, unneeded or
dangerous cells from the body. Through a deep
knowledge of apoptosis and the role impaired
apoptosis can play in the proliferation of cancer cells,
Abbvie is advancing novel cancer research.
• A highly controlled process for eliminating
unneeded or damaged cells in response to
developmental cues, cellular stress, or injury.
• A way that homeostasis is regulated and
maintained in adult tissues.
• Instrumental in safeguarding the integrity of the
genome in response to severe DNA damage
Neuroscience
Richard A. Gonzalez
CEO & Chairman
“
Abbvie is advancing research across several
neurodegenerative disorders, including Alzheimer’s
disease, multiple sclerosis and Parkinson’s disease.
Alzheimer’s disease
As the number of patients and caregivers seeking
help from the health care system increases, Alzheimer’s
represents a growing challenge for society. Current
treatments simply address the symptoms and do nothing
to prevent the progression of the disease or reverse the
damage. Abbvie is collaborating with the world’s leading
Alzheimer’s researchers to identify ways of stopping
the disease in its earliest stages. Its anti-tau antibody
is being investigated to treat Alzheimer’s disease and
progressive supranuclear palsy (PSP) and is advancing
to phase 2 developments.
Multiple Sclerosis
Multiple sclerosis, or MS, is a progressive chronic
disorder of the nervous system that is most often
seen in patients between the ages of 20 and 40.
We’re a company that
takes on the toughest
health challenges.
”
In MS, the immune system attacks a protein called
myelin, which forms a protective sheet around
neurofibers. When myelin is damaged by MS, neurons
struggle to communicate, leading to an accumulation
of neuronal loss, atrophy and significant disability
over time. Abbvie is committed to meeting the needs
of patients with MS, and it is currently supporting
treatment options that promote nerve protection and
facilitate neuronal regeneration.
Parkinson’s disease
Parkinson’s disease is the second most-common
neurodegenerative disorder, affecting more than 10
million people worldwide. In addition to its therapy for
advanced Parkinson’s, Abbvie is currently exploring
other pathways that could provide patients with a new
method of treatment for this progressive chronic disease.
It is also developing a new delivery system to enhance
the patient and caregiver experience while administering
its existing therapy for Parkinson’s disease. SR
115